Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
3
Active, not recruiting, industry sponsors, Kidney and urology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed133
3 trials
Showing 1 to 3, recently updated first.
- A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney DiseaseActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06610526 · 731 participants · Start Aug 23, 2024 · Primary completion May 31, 2027
Drug: Dapagliflozin · For: Chronic Kidney Disease
Sites: Beijing, China; Changchun, China; Dongguan, China · 34 sites in all
- Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA NephropathyActive, not recruiting
Asahi Kasei Therapeutics, ABIndustry
NCT06712407 · 60 participants (planned) · Start Dec 17, 2024 · Primary completion Mar 2027
Drug: TARPEYO® · For: IgA Nephropathy
Sites: Birmingham, Alabama; Glendale, Arizona; Fresno, California · 38 sites in all
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisActive, not recruiting
Travere Therapeutics, Inc.Industry
NCT07219121 · 20 participants (planned) · Start Oct 7, 2025 · Primary completion Mar 2027
Drug: Sparsentan · For: Proteinuria; Immunoglobulin A (IgA) Nephropathy; Focal Segmental Glomerulosclerosis and 1 more
Sites: Birmingham, Alabama; New York, New York; Morrisville, North Carolina · 8 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.